TABLE 1.
Experimental Design
| Group | Monkey | Weight (kg) | Age (y) | Injected 89Zr dose (MBq) | Imaging time point after injection (d) |
| 89Zr-DFO-Bz-NCS–anti-gD | A | 2.87 | 1.2 | 37.4 | 0, 2, 7, 14, 20, 30 |
| B | 2.87 | 1.2 | 36.2 | ||
| C | 3.55 | 1.5 | 38.8 | ||
| 89Zr-DFO*-Bz-NCS–anti-gD | A | 3.16 | 1.5 | 39.5 | 0, 3, 7, 17, 21, 31 |
| B | 3.35 | 1.8 | 36.6 | ||
| C | 3.77 | 2.0 | 37.4 | ||
| 89Zr-DFO-squaramide–anti-gD | A | 1.75 | 1.0 | 42.0 | 0, 3, 6, 14, 21, 29 |
| B | 1.92 | 1.0 | 42.4 | ||
| C | 2.24 | 1.0 | 43.6 | ||
| 89Zr-DFO*-squaramide–anti-gD | A | 3.00 | 1.3 | 47.1 | 0, 3, 7, 14, 21, 31 |
| B | 2.62 | 1.2 | 40.7 | ||
| C | 2.25 | 1.2 | 41.8 |